Bio-Rad Laboratories Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel

Bio-Rad Laboratories has announced the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel, for research use only (RUO).

The qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens, enabling vaccine developers to determine therapeutic efficacy from development through all clinical phases. In addition, the kit enables public health researchers to perform seroprevalence studies. This could help to identify the number of persons in a population who have been exposed to SARS-CoV-2 based on serology specimens, capturing individuals who have not received a COVID-19 diagnosis due to experiencing only mild symptoms or being asymptomatic.

The product is a ready-to-use 96-well kit containing premixed magnetic capture beads, an IgG-specific detection antibody, positive and negative controls, and buffers that produce results for four anti–SARS-Cov-2 antibodies using only 5 uL of sample. The offering includes singleplex assay reagents, enabling measurement of specific viral antigens of interest, and is designed to improve laboratory efficiency by generating key actionable data in a single experiment. The kit is compatible with RUO Bio-Rad platforms, including the Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, as well as all other RUO xMAP platforms.

The kit helps researchers simultaneously profile antibodies against four SARS-CoV-2 viral antigens in under 3 h and confirms detectable IgG levels based on median fluorescence intensity (MFI) cut-off values. It enables comparison of MFI values of samples to help researchers and vaccine developers understand both the strength of response and antibody levels at different time points after SARS-CoV-2 infection or vaccination. The coupled beads can be used to measure antibodies in any species, making the assay useful for both preclinical and clinical trials.